Norgine Holds Out Cetilistat Hope As Takeda Alliance Ends In Challenging Japan Market

Takeda and Norgine’s decision to finally end their alliance for cetilistat in Japan, years after the obesity drug was approved in its first potential market, serves as another sign of the sector’s challenges in the country.